

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number
WO 01/87841 A1

- (51) International Patent Classification⁷: C07D 213/74, A61K 31/44, A61P 7/10
- (21) International Application Number: PCT/HR00/00033
- (22) International Filing Date:
25 September 2000 (25.09.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
P20000328A 19 May 2000 (19.05.2000) HR
- (71) Applicant (*for all designated States except US*): **PLIVA, FARMACEUTSKA INDUSTRIJA, DIONIČKO DRUČTVO** [HR/HR]; Ulica grada Vukovara 49, H-10000 Zagreb (HR).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **FILIĆ, Darko** [HR/HR]; Marice Barić 17, 10000 Zagreb (HR). **DUMIĆ, Miljenko** [HR/HR]; Ivane Brlić Mažuranić 4, 10000 Zagreb (HR). **KLEPIČ, Božena** [HR/HR]; Petra Skoka 8, 10450 Jastrebarsko (HR). **DANILOVSKI, Aleksandar** [HR/HR]; Rastočine 4/VI, 51000 Rijeka (HR). **TUDJA, Marijan** [HR/HR]; Koste Racina 3, 10000 Zagreb (HR).
- (74) Common Representative: **PLIVA, FARMACEUTSKA INDUSTRIJA, DIONIČKO DRUSTVO**; Pravni poslovi, Vesna Vasiljevic, Ulica grada Vukovara 49, H-10000 Zagreb (HR).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *with international search report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/87841 A1

(54) Title: NOVEL POLYMORPH V OF TORASEMIDE

(57) Abstract: The invention relates to a novel polymorph V of torasemide, to a process for its preparation, to its use as a raw material for the preparation of crystalline modifications I and III of torasemide, to amorphous torasemide modifications and to pharmaceutically acceptable salts of torasemide, to pharmaceutical forms containing the said novel polymorph V of torasemide as the active ingredient as well as to its use.

BEST AVAILABLE COPY

WO 01/87841

PCT/HR00/00033

Novel Polymorph V of Torasemide

The present invention relates to a novel crystalline form of *N*-(1-methylethyl aminocarbonyl)-4-(3-methyl-phenylamino)-3-pyridinesulfonamide (further referred to by its generic name "torasemide"), especially to a novel polymorph V of torasemide, to a process for its preparation, to its use as a raw material for the preparation of crystalline modifications I and III of torasemide, to amorphous torasemide modifications and to pharmaceutically acceptable salts of torasemide, to pharmaceutical forms containing the said novel polymorph V of torasemide as the active ingredient as well as to its use.

Torasemide is a new potent diuretic in the class of the so-called "loop diuretics", which is described in DE patent 25 16 025 (Example 71). Structurally, it entirely differs from diuretics of the same class such as furosemide, bumetanide and azosemide. In addition to diuretic properties it also possesses antihypertensive properties.

As a diuretic of Henle's loop it is useful as an agent for preventing heart or heart tissue damages caused by metabolic or ionic abnormalities associated with ischemia, in the treatment of thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema, primary and secondary aldosteronism, Bartter's syndrome, tumours, glaucoma, decreasing of intraocular pressure, acute or chronic bronchitis, in the treatment of cerebral edema caused by trauma, ischemia, concussion of the brain, metastases or epileptic attacks and in the treatment of nasal infections caused by allergens.

The ability of a substance to exist in more than one crystalline form is defined as polymorphism and these different crystalline forms are named "polymorph modifications" or "polymorphs". In general, polymorphism is caused by the ability of the molecule of a substance to change its conformation or to form different inter-

WO 01/87841

PCT/HR00/00033

2

molecular and intramolecular interactions, particularly hydrogen bonds, which is reflected in different atom arrangements in the crystal lattices of different polymorphs. Polymorphism is found in several organic compounds. Among medicaments polymorphism is found in about 70% of barbiturates, 60% of sulfonamides and 60% of steroids, and about 50% of medicaments of the said classes are not present on the market in their most stable forms (T. Laird, Chemical Development and Scale-up in the Fine Chemical Industry, Principles and Practices, Course Manual, Scientific Update, Wyvern Cottage, 1996).

The different polymorphs of a substance possess different energies of the crystal lattice and, thus, they show different physical properties of the solid state such as form, density, melting point, colour, stability, dissolution rate, milling facility, granulation, compacting etc., which in medicaments may affect the possibility of the preparation of pharmaceutical forms, their stability, dissolution and bioavailability and, consequently, their action.

Polymorphism of medicaments is the object of studies of interdisciplinary expert teams [J. Halebian, W. McCrone, *J. Pharm. Sci.* **58** (1969) 911; L. Borka, *Pharm. Acta Helv.* **66** (1991) 16; M. Kuhnert-Brandstätter, *Pharmazie* **51** (1996) 443; H. G. Brittain, *J. Pharm. Sci.* **86** (1997) 405; W. H. Streng, *DDT* **2** (1997) 415; K. Yoshii, *Chem. Pharm. Bull.* **45** (1997) 338, etc.]. A good knowledge of polymorphism represents a precondition for a critical observation of the whole process of medicament development. Thus, at deciding on the production of a pharmaceutical form in solid state and with regard to the dose size, stability, dissolution and anticipated action, it is necessary to determine the existence of all solid state forms (on the market some computer programmes can be found, e.g. »Polymorph« as a module of »Cerius2« programme, MSI Inc., USA) and to determine the physical-chemical properties of each of them. Only on the basis of these determinations the appropriate polymorph can be selected for the development of pharmaceutical formulations of desired properties.

WO 01/87841

PCT/HR00/00033

3

From the great number of such efforts only a few will be mentioned as an example. Thus, Gordon et al. (US 4,476,248) protected a novel crystalline form of ibuprofen and a process for the preparation thereof. Bunnell et al. (EP 733,635) protected a novel crystalline form, a process for the preparation thereof and pharmaceutical formulations of the drug olanzapine containing the said novel form. R. B. Gandhi et al. (EP 749,969) protected a novel process for the preparation of a polymorphous form I of stavudine from a mixture of one or more forms I, II and III, whereas A. Caron et al. (EP 708,103) protected a novel crystalline form of irbesartane, a process for the preparation thereof as well as pharmaceutical formulations containing this crystalline form. Chikaraishi et al. (WO 9626197) protected, in addition to a polymorphous form, also an amorphous form of piretanide as well as processes for the preparation thereof. J.-B. Cha et al. (WO 9857967) protected an amorphous form, a process for the preparation thereof and pharmaceutical formulations of the medicament itraconazole containing this amorphous form, whereas E. Occeli et al. (WO 90/00553) protected crystal polymorphs I and II and amorphs of the medicament rifapentine hydrochloride and hydrobromide. Further, for the new antidiabetic troglitazone G. Om Reddy et al. (US 5,700,820) protected six polymorphs: five crystal polymorphs and one amorphous one.

It is known that torasemide can exist in three crystalline modifications differing with regard to the parameters of a unit cell, which is confirmed by X-ray diffraction on their monocrystals, and in one amorphous modification (HR patent application P20000162A). Modification I with melting point 169°C [*Acta Cryst.* B34 (1978), 1304-1310] and modification III with melting point 165°C (WO 00/20395) crystallize monoclinically in the space group $P 2_1/c$ (prisms), while modification II with melting point 162°C crystallizes monoclinically in the space group $P 2/n$ (foils) [*Acta Cryst.* B34 (1978), 2659-2662].

In addition to the above, US patent 5,914,336 protected the use of a new torasemide polymorph, however, only some of its physical-chemical properties such as melting point, heat of formation, solubility, first band in IR-spectrum, but no X-ray patterns of the powder and monocrystals were stated therein. Since the data as stated are not

WO 01/87841

PCT/HR00/00033

4

relevant for the characterization of polymorphism, the claimed subject-matter of US 5,914,336 is not believed to be reliable.

In our further research in the field of torasemide we have surprisingly found a novel crystalline torasemide modification, i.e. a novel polymorph V of torasemide which has hitherto not been known.

The novel polymorph V of torasemide is prepared according to the inventive process in the form of a flowable crystalline powder having the property of flowability, i.e. it is obtained in a "free-flow" form which is statically not chargeable.

In a solution the novel polymorph V of torasemide is identical to other known torasemide modifications, which is evident from NMR and UV spectra. On the other hand, solid state analysis techniques such as differential scanning calorimetry (DSC), X-ray powder pattern (XRD) and IR spectroscopy reveal a difference in comparison to the known torasemide modifications.

DSC of the novel polymorph V of torasemide (Fig. 1) shows one exothermic maximum at about 157.59°C (onset at about 150.74°C) (heating rate of 10°C/min) resulting from decomposition (also evident on the basis of IR spectroscopy and thin-layer chromatography).

The X-ray powder pattern of the novel polymorph V of torasemide differs from the X-ray powder patterns of the known torasemide modifications (Fig. 2).

The IR spectrum of a sample of the novel polymorph V of torasemide recorded in KBr (Fig. 3) differs from IR spectra of the known torasemide modifications. The novel polymorph V of torasemide shows characteristic absorption bands at 2671 to 3327 cm^{-1} and at 1468 to 1705 cm^{-1} .

Fig. 1 represents a characteristic thermogram of differential scanning calorimetry (DSC) of the novel polymorph V of torasemide.

WO 01/87841

PCT/HR00/00033

5

Fig. 2 represents a characteristic X-ray powder pattern of the novel polymorph V of torasemide.

Fig. 3 represents a characteristic IR spectrum of the novel polymorph V of torasemide recorded in KBr.

The novel polymorph V of torasemide according to the present invention can be obtained by a rapid acidification of alkaline torasemide solutions with inorganic or organic acids.

A process for the preparation of the novel polymorph V of torasemide comprises:

- (i) the preparation of a polymorph I of torasemide according to a known process,
 - (ii) the dissolution of the polymorph I of torasemide in an aqueous solution of a base,
 - (iii) the filtration of the obtained solution,
 - (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0°C and 35°C,
 - (v) the filtration of the obtained suspension,
 - (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50°C, the obtained crystals being characterized by the following data:
- DSC: exothermic maximum at about 157.59°C (onset at about 150.74°C) (Fig. 1);
 - X-ray powder pattern (2 Θ): 5.610; 6.130; 7.480; 7.970; 9.310; 9.615; 10.835; 11.020; 12.340; 13.075; 13.460; 13.920; 14.200; 15.090; 16.080; 16.710; 17.445; 17.720; 18.460; 18.850; 19.825; 20.340; 20.990; 21.980; 22.075; 22.630; 22.935; 23.410; 23.845; 24.880; 25.560; 26.035; 27.285; 27.540; 28.170; 28.645; 29.350; 29.975; 30.575; 31.265; 32.300; 34.050; 35.650; 36.375; 37.100, and 38.145 (Fig. 2);
 - IR-characteristic absorption bands (cm^{-1}): at 2671 to 3327 and at 1468 to 1705 (Fig. 3).

WO 01/87841

PCT/HR00/00033

6

According to a further embodiment of the present invention, a process for the preparation of the novel polymorph V of torasemide also comprises:

- (i) the preparation of a polymorph II of torasemide according to a known process,
- (ii) the dissolution of the polymorph II of torasemide in an aqueous solution of a base,
- (iii) the filtration of the obtained solution,
- (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0°C and 35°C,
- (v) the filtration of the obtained suspension,
- (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50°C, the obtained crystals being characterized by the data represented in the previous process.

According to a further embodiment of the present invention, a process for the preparation of the novel polymorph V of torasemide also comprises:

- (i) the preparation of a polymorph III of torasemide according to a known process,
- (ii) the dissolution of the polymorph III of torasemide in an aqueous solution of a base,
- (iii) the filtration of the obtained solution,
- (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0°C and 35°C,
- (v) the filtration of the obtained suspension,
- (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50°C, the obtained crystals being characterized by the data represented in the previous process.

According to a further embodiment of the present invention, a process for the preparation of the novel polymorph V of torasemide also comprises:

- (i) the preparation of an amorphous torasemide modification according to a known process,
- (ii) the dissolution of the amorphous torasemide modification in an aqueous solution of a base,
- (iii) the filtration of the obtained solution,

WO 01/87841

PCT/HR00/00033

7

- (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0°C and 35°C,
- (v) the filtration of the obtained suspension,
- (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50°C, the obtained crystals being characterized by the data represented in the previous process.

According to a further embodiment of the present invention, a process for the preparation of the novel polymorph V of torasemide also comprises:

- (i) the preparation of a novel polymorph V of torasemide according to the process of the present invention,
- (ii) the dissolution of the novel polymorph V of torasemide in an aqueous solution of a base,
- (iii) the filtration of the obtained solution,
- (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0°C and 35°C,
- (v) the filtration of the obtained suspension,
- (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50°C, the obtained crystals being characterized by the data represented in the previous process.

According to a further embodiment of the present invention, a process for the preparation of the novel polymorph V of torasemide also comprises:

- (i) the preparation of polymorphs I, II and III of torasemide according to known processes, the preparation of an amorphous torasemide modification according to a known process and the preparation of the novel polymorph V of torasemide according to the process of the present invention,
- (ii) the dissolution of any mixture of the polymorphs I, II and III of torasemide, of the amorphous torasemide modification or the novel polymorph V of torasemide in an aqueous solution of a base,
- (iii) the filtration of the obtained solution,

WO 01/87841

PCT/HR00/00033

8

- (iv) a rapid acidification of the obtained solution with an aqueous solution of an acid at temperatures between 0°C and 35°C,
- (v) the filtration of the obtained suspension,
- (vi) washing the thus obtained crystals of the novel polymorph V of torasemide with demineralized water and drying them in a vacuum dryer during 3 hours at 50°C, the obtained crystals being characterized by the data represented in the previous process.

According to the present process, aqueous solutions of lithium hydroxide, sodium hydroxide and potassium hydroxide as well as aqueous solutions of sodium carbonate and potassium carbonate may be used for the preparation of alkaline solutions of torasemide modifications.

The acidification of alkaline torasemide solutions may, according to the present process, be carried out with inorganic acids such as hydrochloric, sulfuric, phosphoric and nitric acids, and with organic acids such as formic, acetic, propionic, oxalic, tartaric, methanesulfonic and p-toluenesulfonic acids.

It has also been established that at using the present process no decomposition of torasemide takes place, i.e. a chemically pure novel polymorph V of torasemide (TLC and HPLC) is obtained.

It has been additionally established that under normal storage conditions the novel polymorph V of torasemide is stable at milling and pressing, i.e. it is not transformed into crystalline modifications I, II and III of torasemide or into an amorphous torasemide modification.

The novel polymorph V of torasemide prepared according to the present process may be converted to crystalline modifications I, II or III of torasemide or to an amorphous torasemide modification according to conventional processes, i.e. it may serve as a starting material for the preparation of well-known crystalline modifications I, II or III of torasemide or an amorphous torasemide modification.

WO 01/87841

PCT/HR00/00033

9

The novel polymorph V of torasemide prepared according to the present invention may be converted into pharmaceutically acceptable salts of torasemide in a well-known manner.

The examination of the release (USP 24) of the novel polymorph V of torasemide in water in comparison with the release profile of known crystalline torasemide modifications in the same medium revealed a slower release thereof. This makes the novel polymorph V of torasemide suitable for the preparation of pharmaceutical preparations having immediate or prolonged action.

The novel polymorph V of torasemide prepared according to the present process may be, as a suitable torasemide form, used as a diuretic or as an agent for preventing heart or heart tissue damages caused by metabolic or ionic abnormalities associated with ischemia, in the treatment of thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema, primary and secondary aldosteronism, Bartter's syndrome, tumours, glaucoma, decreasing of intraocular pressure, acute or chronic bronchitis, in the treatment of cerebral edema caused by trauma, ischemia, concussion of the brain, metastases or epileptic attacks and in the treatment of nasal infections caused by allergens.

The present invention also relates to pharmaceutical forms such as tablets, capsules or injections containing an effective amount of the novel polymorph V of torasemide as an active ingredient, without or in combination with one or more pharmaceutically acceptable additives such as sugar, starch, starch derivatives, cellulose, cellulose derivatives, mould release agents, and antiadhesive agents and, possibly, agents for regulating flowability.

The present invention is illustrated by the following non-limiting Examples.

Example 1

WO 01/87841

PCT/HR00/00033

10

The crystalline modification I of torasemide (1.0 g) prepared according to *Acta Cryst. B34* (1978) 1304-1310, was dissolved in a 5% aqueous sodium hydroxide solution (3 ml) and then at the temperature of 20°C the solution was acidified for 15 seconds with a 5% aqueous hydrochloric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50°C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155°C was obtained.

The characteristic DSC curve of the sample as shown in Fig. 1 was recorded on the apparatus Perkin-Elmer DSC7 at a heating rate of 10°C/minute.

The characteristic X-ray powder pattern as shown in Fig. 2 was recorded on the instrument PHILIPS PW3710 under Cu X-rays [$\lambda(\text{CuK}\alpha_1) = 1.54046 \text{ \AA}$ and $\lambda(\text{CuK}\alpha_2) = 1.54439 \text{ \AA}$].

The characteristic IR spectrum of the sample as shown in Fig. 3 was recorded in KBr on the IR-spectrophotometer Nicolet-Magna 760.

Example 2

The crystalline modification II of torasemide (1.0 g) prepared according to *Acta Cryst. B34* (1978) 1304-1310, was dissolved in a 5% aqueous potassium hydroxide solution (3 ml) and then at the temperature of 20°C the solution was acidified for 15 seconds with a 10% aqueous acetic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50°C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155°C was obtained.

The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.

Example 3

WO 01/87841

PCT/HR00/00033

11

The crystalline modification III of torasemide (10.0 g) prepared according to WO 00/20395, was dissolved in a 10% aqueous sodium carbonate solution (30 ml) and then at the temperature of 20°C the solution was acidified for 60 seconds with a 5% aqueous sulfuric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50°C. A chemically pure novel polymorph V of torasemide (8.1 g), m.p. 153-155°C was obtained.

The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.

Example 4

The amorphous torasemide modification (10.0 g) prepared according to HR patent application P20000162A, was dissolved in a 10% aqueous potassium carbonate solution (30 ml) and then at the temperature of 20°C the solution was acidified for 90 seconds with a 10% aqueous tartaric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50°C. A chemically pure novel polymorph V of torasemide (8.0 g), m.p. 153-155°C was obtained.

The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.

Example 5

The novel polymorph V of torasemide (10.0 g) according to Example 3 of the present invention was dissolved in a 5% aqueous lithium hydroxide solution (30 ml) and then at the temperature of 20°C the solution was acidified for 120 seconds with a 5% aqueous phosphoric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50°C. A

WO 01/87841

PCT/HR00/00033

12

chemically pure novel polymorph V of torasemide (7.9 g), m.p. 153-155°C was obtained.

The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.

Example 6

A mixture (1.0 g) of crystalline modifications I and II of torasemide prepared according to *Acta Cryst. B34* (1978) 1304-1310, was dissolved in a 10% aqueous sodium carbonate solution (3 ml) and then at the temperature of 20°C the solution was acidified for 15 seconds with a 5% aqueous p-toluenesulfonic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50°C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155°C was obtained.

The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.

Example 7

A mixture (1.0 g) of crystalline modifications I and III of torasemide prepared according to *Acta Cryst. B34* (1978) 1304-1310 and WO 00/20395, was dissolved in a 5% aqueous sodium hydroxide solution (3 ml) and then at the temperature of 20°C the solution was acidified for 15 seconds with a 5% aqueous nitric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50°C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155°C was obtained.

The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.

WO 01/87841

PCT/HR00/00033

13

Example 8

A mixture (1.0 g) of crystalline modifications II and III of torasemide prepared according to *Acta Cryst. B34* (1978) 1304-1310 and WO 00/20395, was dissolved in a 5% aqueous potassium hydroxide solution (3 ml) and then at the temperature of 20°C the solution was acidified for 15 seconds with a 10% aqueous propionic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50°C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155°C was obtained.

The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.

Example 9

A mixture (1.0 g) of crystalline modifications I, II and III of torasemide prepared according to *Acta Cryst. B34* (1978) 1304-1310 and WO 00/20395, was dissolved in a 5% aqueous lithium hydroxide solution (3 ml) and then at the temperature of 20°C the solution was acidified for 15 seconds with a 10% aqueous oxalic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50°C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155°C was obtained.

The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.

Example 10

A mixture (1.0 g) of a crystalline modification I of torasemide and an amorphous torasemide modification prepared according to *Acta Cryst. B34* (1978) 1304-1310 and HR patent application P20000162A, was dissolved in a 10% aqueous sodium carbonate solution (3 ml) and then at the temperature of 20°C the solution was

WO 01/87841

PCT/HR00/00033

14

acidified for 15 seconds with a 5% aqueous methanesulfonic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50°C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155°C was obtained.

The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.

Example 11

A mixture (1.0 g) of a crystalline modification I of torasemide and of the novel polymorph V of torasemide prepared according to *Acta Cryst. B34* (1978) 1304-1310 and according to Example 1 of the present invention, was dissolved in a 10% aqueous potassium carbonate solution (3 ml) and then at the temperature of 20°C the solution was acidified for 15 seconds with a 5% aqueous hydrochloric acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried in a vacuum dryer for 3 hours at 50°C. A chemically pure novel polymorph V of torasemide (0.9 g), m.p. 153-155°C was obtained.

The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.

Example 12

A mixture (10.0 g) of crystalline modifications I, II and III of torasemide, of an amorphous torasemide modification and of the novel polymorph V of torasemide prepared according to *Acta Cryst. B34* (1978) 1304-1310, WO 00/20395, HR patent application P20000162A and Example 1 of the present invention, was dissolved in a 5% aqueous sodium hydroxide solution (30 ml) and then at the temperature of 20°C the solution was acidified for 60 seconds with a 10% aqueous acetic acid solution. The crystals were sucked off, washed with demineralized water and acetone and dried

WO 01/87841

PCT/HR00/00033

15

in a vacuum dryer for 3 hours at 50°C. A chemically pure novel polymorph V of torasemide (8.0 g), m.p. 153-155°C was obtained.

The IR spectrum of the sample thus obtained corresponded to the IR spectrum of the novel polymorph V of torasemide obtained according to Example 1.

Example 13

The novel polymorph V of torasemide obtained according to Example 1 of the present invention was subjected to testing the release of the active substance in water at the temperature of 37°C (USP 24) and the results are given in Table 1.

Table 1: Release of the novel polymorph V of torasemide in water (USP 24) (37°C, 50 rpm, 1000 ml)

Time (min)	Released torasemide (%)
0	0
15	11.3
30	20.5
45	26.0
60	30.0
90	36.0
120	40.7

WO 01/87841

PCT/HR00/00033

17

CLAIMS

1. Novel polymorph V of torasemide characterized by the following data:
DSC: exothermic maximum at about 157.59°C (onset at about 150.74°C) with the heating rate of 10°C/min;
X-ray powder pattern (2 Θ): 5.610; 6.130; 7.480; 7.970; 9.310; 9.615; 10.835; 11.020; 12.340; 13.075; 13.460; 13.920; 14.200; 15.090; 16.080; 16.710; 17.445; 17.720; 18.460; 18.850; 19.825; 20.340; 20.990; 21.980; 22.075; 22.630; 22.935; 23.410; 23.845; 24.880; 25.560; 26.035; 27.285; 27.540; 28.170; 28.645; 29.350; 29.975; 30.575; 31.265; 32.300; 34.050; 35.650; 36.375; 37.100, and 38.145;
IR-characteristic absorption bands at 2671 to 3327 and at 1468 to 1705 cm^{-1} .
2. Novel polymorph V of torasemide according to claim 1, characterized in that it is chemically pure.
3. Novel polymorph V of torasemide according to claim 1, characterized in that it contains no water.
4. Novel polymorph V of torasemide according to claim 1, characterized in that it contains no solvent.
5. Process for the preparation of the novel polymorph V of torasemide according to claim 1, characterized in that an alkaline solution of torasemide is subjected to a rapid acidification with inorganic or organic acids at temperatures between 0°C and 35°C.
6. Process for the preparation of the novel polymorph V of torasemide according to claim 5, characterized in that as torasemide modifications there are used crystalline modifications I, II and III of torasemide, an amorphous torasemide modification or the novel polymorph V of torasemide or any mutual mixture of

WO 01/87841

PCT/HR00/00033

18

crystalline modifications I, II and III of torasemide, an amorphous torasemide modification or the novel polymorph V of torasemide.

7. Process for the preparation of the novel polymorph V of torasemide according to claim 5, characterized in that for the preparation of alkaline solutions of torasemide aqueous solutions of lithium hydroxide, sodium hydroxide and potassium hydroxide as well as aqueous solutions of sodium carbonate and potassium carbonate are used.
8. Process for the preparation of the novel polymorph V of torasemide according to claim 5, characterized in that for the acidification inorganic acids such as hydrochloric, sulfuric, phosphoric or nitric acid, and organic acids such as formic, acetic, propionic, oxalic, tartaric, methanesulfonic or p-toluenesulfonic acid are used.
9. Novel polymorph V of torasemide according to claim 1, characterized in that it is used as a raw material for the preparation of the crystalline modifications I, II and III torasemide or of an amorphous torasemide modification.
10. Novel polymorph V of torasemide according to claim 1, characterized in that it is used as a raw material for the preparation of pharmaceutically acceptable salts of torasemide.
11. Novel polymorph V of torasemide according to claim 1, characterized in that it may be used as a suitable torasemide form serving as a diuretic or as an agent for preventing heart or heart tissue damages caused by metabolic or ionic abnormalities associated with ischemia, in the treatment of thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema, primary and secondary aldosteronism, Bartter's syndrome, tumours, glaucoma, decreasing of intraocular pressure, acute or chronic bronchitis, in the treatment of cerebral edema caused by trauma, ischemia, concussion of the brain, metastases or epileptic attacks and in the treatment of nasal infections caused by allergens.

WO 01/87841

PCT/HR00/00033

19


12. Pharmaceutical form, characterized in that as an active ingredient it contains an effective amount of the novel polymorph V of torasemide according to claim 1, without or in combination with one or more pharmaceutically acceptable additives such as sugar, starch, starch derivatives, cellulose, cellulose derivatives, mould release agents, and antiadhesive agents and possibly agents for regulating flowability.
13. Pharmaceutical form according to claim 12, characterized in that it is a tablet, a capsule or an injection.

WO 01/87841

PCT/HR00/00033

1/3

Fig. 1: DSC of the novel polymorph V of torasemide




WO 01/87841

PCT/HR00/00033

2/3

Fig. 2: X-ray powder pattern of a sample of the novel polymorph V of torasemide




WO 01/87841

PCT/HR00/00033

3/3

Fig. 3: IR spectrum of the novel polymorph V of torasemide recorded in KBr



INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/HR 00/00033

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D213/74 A61K31/44 A61P7/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 914 336 A (DRECKMANN-BEHRENDT BRUNO) 22 June 1999 (1999-06-22) cited in the application the whole document	1,5,9-13
X	WO 00 20395 A (PLIVA FARMACEUTSKA IND DIONI &) 13 April 2000 (2000-04-13) cited in the application claims 1,6,14,15	1,5,11, 12
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance.

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

1 February 2001

Date of mailing of the international search report

15/02/2001

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/HR 00/00033

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MASEREEL B ET AL: "Synthesis and pharmacology of pyrid-3-ylsulfonylcyanoguanidines as diuretics" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, CHIMICA THERAPEUTICA, FR, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, vol. 30, no. 4, 1995, pages 343-351, XP004040154 ISSN: 0223-5234 table V	1
A	DE 25 16 025 A (CHRISTIAENS SA A) 6 November 1975 (1975-11-06) cited in the application example 71	1,5,9-13
A	DUPONT L ET AL: "Structure cristalline et moléculaire d'un diurétique dérivé de l'alkyl-1'(phénylamino-4-pyridyl-3)sulfonyl-1-3 urée: la torasémide (C ₁₅ H ₂₀ N ₄ O ₃)" ACTA CRYSTALLOGRAPHICA. SECTION B, STRUCTURAL CRYSTALLOGRAPHY AND CRYSTAL CHEMISTRY, DK, MUNKSGAARD, COPENHAGEN, vol. B34, no. 4, April 1978 (1978-04), pages 1304-1310, XP002128455 ISSN: 0567-7408 cited in the application the whole document	1
A	DUPONT L ET AL: "Structure d'une seconde variété de la torasémide" ACTA CRYSTALLOGRAPHICA. SECTION B, STRUCTURAL CRYSTALLOGRAPHY AND CRYSTAL CHEMISTRY, DK, MUNKSGAARD, COPENHAGEN, vol. B34, no. 8, August 1978 (1978-08), pages 2659-2662, XP002128456 ISSN: 0567-7408 cited in the application the whole document	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/HR 00/00033

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5914336 A	22-06-1999	NONE	
WO 0020395 A	13-04-2000	HR 980532 A	31-12-2000
		AU 6224099 A	26-04-2000
DE 2516025 A	06-11-1975	GB 1477664 A	22-06-1977
		YU 150781 A	29-02-1984
		AR 211097 A	31-10-1977
		AR 208768 A	28-02-1977
		AR 208769 A	28-02-1977
		AR 208770 A	28-02-1977
		AT 344174 B	10-07-1978
		AT 189777 A	15-11-1977
		AT 345832 B	10-10-1978
		AT 189877 A	15-02-1978
		AT 344175 B	10-07-1978
		AT 189977 A	15-11-1977
		AT 344170 B	10-07-1978
		AT 288275 A	15-11-1977
		AU 8001675 A	14-10-1976
		BE 827844 A	13-10-1975
		CA 1070313 A	22-01-1980
		CH 610890 A	15-05-1979
		CH 612424 A	31-07-1979
		CH 609045 A	15-02-1979
		DD 121936 A	05-09-1976
		DD 126887 A	17-08-1977
		ES 436581 A	01-04-1977
		ES 453327 A	16-11-1977
		ES 453328 A	01-11-1977
		ES 453329 A	16-11-1977
		FR 2267775 A	14-11-1975
		HU 171420 B	28-01-1978
		IL 47084 A	31-01-1979
		JP 1275160 C	31-07-1985
		JP 50142571 A	17-11-1975
		JP 59051536 B	14-12-1984
		LU 72284 A	20-08-1975
		LU 88346 A	04-05-1994
		MX 4679 E	28-07-1982
		NL 7504521 A, B,	21-10-1975
		SE 424320 B	12-07-1982
		SE 7504409 A	20-10-1975
		SE 7907618 A	13-09-1979
		US RE30633 E	02-06-1981
		US 4018929 A	19-04-1977
		US 4055650 A	25-10-1977
		YU 95675 A	28-02-1982
		ZA 7502243 A	31-03-1976

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☒ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.